Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
Amalia SchiavettiGiulia VarrassoMaria Giovanna MollaceCarlo DominiciEva FerraraPaola PapoffClaudio Di BiasiPublished in: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2019)
BVZ/IRI association ± TMZ showed encouraging therapeutic activity and low toxicity in this series of relapsed/refractory brain tumors.